Image may be NSFW.
Clik here to view.
Seattle biotech Omeros closed 2015 with $13.5 million in revenue, $13.3 million of which came from sales of its first drug, Omidria, the company reported.
For the fourth quarter, sales of Omidria totaled $6.7 million, or more than double third-quarter sales. The $6.7 million in sales revenue compares with grant revenue of $180,000 for the same quarter the prior year.
Launched widely in the U.S. in April 2015, Omidria is a drug used during cataract surgery to maintain pupil size and reduce post-surgery…
Clik here to view.
Seattle biotech Omeros closed 2015 with $13.5 million in revenue, $13.3 million of which came from sales of its first drug, Omidria, the company reported.
For the fourth quarter, sales of Omidria totaled $6.7 million, or more than double third-quarter sales. The $6.7 million in sales revenue compares with grant revenue of $180,000 for the same quarter the prior year.
Launched widely in the U.S. in April 2015, Omidria is a drug used during cataract surgery to maintain pupil size and reduce post-surgery…
